A Phase I Open-label, Multiple Dose Study of CHO-H01 Administered Intravenously as a Single Agent to Subjects With Refractory or Relapsed Follicular Lymphoma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs CHO H01 (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors CHO Pharma
- 23 Jan 2018 Planned initiation date changed from 1 Oct 2017 to 1 Mar 2018.
- 21 Jul 2017 New trial record